DC-CIK联合氟尿嘧啶+顺铂化疗对局部进展期宫颈癌术后患者的疗效及安全性

摘要

目的:探讨DC-CIK联合氟尿嘧啶+顺铂化疗对局部进展期宫颈癌术后患者的影响.方法:2012年1月至2015年1月,前瞻性收集我院收治的局部进展期宫颈癌患者96例,均行宫颈癌根治术,术后将患者随机分为观察组和对照组,每组各48例.两组患者均给予氟尿嘧啶+顺铂化疗,观察组在此基础上给予 DC-CIK辅助治疗,观察两组患者临床疗效.结果:观察组患者术后 2年时复发率显著低于对照组(P＝0. 019).两组患者术后死亡率差异无统计学意义(P＞0. 05).与对照组比较,观察组治疗后CD4 +T细胞显著增高(P＝0. 000);CD4 +/CD8 +显著增高(P＝0. 000);CD3 +CD56 +NKT细胞显著增高(P＝0. 000).两组患者术后并发症无统计学差异(P＞0. 05).结论:DC-CIK联合氟尿嘧啶+顺铂化疗可降低局部进展期宫颈术后患者复发率,改善临床预后,安全有效.%Objective:To investigate the effect of DC-CIK combined with fluorouracil+cisplatin chemotherapy on postoperative patients with locally advanced cervical cancer. Methods:From January 2012 to January 2015,96 pa-tients with locally advanced cervical cancer were prospectively collected in our hospital. All patients received radical resection of cervical cancer,and then they were randomly assigned into an observation group or a control group with 48 cases in each group. Patients in the both groups received fluorouracil+cisplatin chemotherapy,and on the basis of this,patients in the observation group received DC-CIK for further treatment. The clinical efficacy of the both groups were studied. Results:When compared with the control group,patients in the observation group got a lower recurrence rate at 2 years since the operation (P＝0. 019). There was no significant differences between the two groups in post-operative mortality (P＞0. 05). Compared with the control group,the observation group after treatment of CD4 +T cells was significantly increased (P＝0. 000). CD4 +/CD8 +increased significantly (P＝0. 000). CD3 +CD56 +NKT cells increased significantly (P＝0. 000). There was no significant difference in postoperative complications between the two groups (P＞0. 05). Conclusion:DC-CIK combined with fluorouracil+cisplatin chemotherapy can reduce the recurrence rate of locally advanced cervical surgery and improve the clinical prognosis,which is safe and effective.